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Cardiovascular pharmacogenetics: On the way to individually extent, individually tailored drug therapy will be offered
tailored drug therapy. G proteins are important mediators of to patients and physicians. The currently established
hormone action in all cells of the human body. Therefore, “trial and error” therapy is uneconomic, and the lackfunctional polymorphisms in genes encoding G protein sub-
of desired drug effects will ultimately be a cause forunits are expected to have a marked influence upon cell activa-
noncompliance observed in many patients.tion and cardiovascular responses to hormones and drugs. The
825T allele of a common C825T polymorphism in the gene, However, these above considerations raise the ques-
GNB3, encoding the G3 subunit, was found to be associated tion as to which single nucleotide polymorphisms (SNPs)
with increased intracellular signal transduction via G protein-
and which genes will be analyzed to achieve that goal?coupled receptors. Originally defined as a candidate gene asso-
Initially, pharmacogenetics has focused on SNPs in theciated with an increased risk for essential hypertension, the
825T allele turns out to be an interesting marker in cardiovascu- huge family of drug-metabolizing enzymes [1]. This ap-
lar pharmacogenetics. Carriers of the 825T allele show an in- pears logical from an historic perspective, as changes in
creased vasoconstriction in the skin microcirculation in re- the individual capacity for drug metabolism (e.g., slow
sponse to noradrenaline, angiotensin II, and endothelin I.
versus fast metabolizers) have long been known to haveCoronary vasoconstriction is enhanced in 825T allele carriers
a significant impact on pharmacokinetics, thereby de-in response to azepexol. On the other hand, some drugs like
hydrochlorothiazide, clonidine, and endothelin receptor antag- termining individual drug concentrations with the poten-
onist evoke increased effects in 825T allele carriers. It appears tial consequence of lacking, or eventually toxic, drug
that the GNB3 C825T polymorphism could be an attractive effects.marker to discriminate responders and nonresponders and
Novel efforts focus on functional SNPs in genes encod-might, therefore, represent an excellent candidate gene in car-
ing drug targets like ion channels, receptors, or signalingdiovascular pharmacogenetics.
proteins. I will focus here on work related to a common
polymorphism in a ubiquitously expressed G protein
subunit, namely the GNB3 C825T polymorphism [2].It is a common experience in cardiovascular drug ther-
apy (e.g., treatment with substances to lower high blood
pressure) that, with all compounds being on the market,
FUNCTION OF G PROTEINS
so far a maximum of 50% to 60% of treated patients
G proteins are heterotrimers composed of -, -, andshows the desired drug effect with a given compound at
-subunits [3]. They are predominantly localized at thea given dose. Conversely, a significant number of patients
plasma membrane and mediate the intracellular signalwill report adverse events ranging from eventually toler-
transduction by heptahelical receptors [4]. The -dimersable mild side effects to severe adverse drug effects.
form a functional monomer, and their composition ofIt is now commonly accepted that, besides nongenetic
various  subunit isoforms is essential for receptor-G-factors, genetic host factors determine, to a large extent,
protein-coupling specificity. On receptor activation, theindividual drug response [1]. Therefore, defining genes to
-subunit releases bound GDP in exchange for GTP,better discriminate responders and nonresponders and
which causes the dissociation of - and -subunits. Boththose patients susceptible to adverse drug reactions will
the -, as well as the -subunits, can inhibit or activate aultimately revolutionize drug therapy. This is the prom-
variety of intracellular effectors, including ion channels,ise of the novel field of pharmacogenetics, which will, in
phospholipases, adenylyl cyclase isoforms, the PI3 ki-the near future, open new horizons in that, to a certain
nase, the MAP kinase pathway, etc. Due to the intrinsic
GTPase activity, the -subunit hydrolyzes bound GTP
Key words: GNB3, G proteins, signal transduction, hypertension. to GDP, - and - subunits re-associate, and the com-
plex is ready for the next activation cycle. Thus, G pro- 2003 by the International Society of Nephrology
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825T allele was strictly associated with a biologically
active splice variant of the G3 protein, generated
through alternative splicing of exon 9, and was termed
G3s. Thus, in cells from homozygous 825C allele carri-
ers, only the “large” protein or mRNA is expressed.
In contrast, both homo- and heterozygous 825T allele
carriers show both the wild-type protein and the short-
ened splice variant. Moreover, the 825T allele was strictly
associated with enhanced G-protein activation. It re-
mained unresolved how a remote nucleotide exchange
in exon 10 could affect splicing of exon 9, especially as
these exons are separated by an intron of 1000 base
pairs. Additional polymorphisms have been detected in
the promoter [7] and in intron 9 which, surprisingly, are
in almost complete linkage disequilibrium [8], as shown
in Fig. 1. These nucleotide exchanges define a complex
“C haplotype” and “T haplotype.” For practical reasons,
the C825T polymorphism can be used for genotyping
due to its one-to-one coupling with the other frequent
Fig. 1. Gene structure of GNB3 and haplotypes. Shown are the haplo- polymorphisms in GNB3. Alternative splicing of GNB3
types C (associated with the 825C-allele) and T (associated with the in 825T allele carriers, thus, seems to result from a com-825 T-allele). Exons are numbered. ATG refers to the start codon;
plex, coordinate interaction of multiple polymorphismsTGA refers to the stop codon; and CACA and CACA refer to
absence or presence of an intronic insert, respectively. Positions of located in intron 9 and exon 10, and modeling studies
polymorphisms are given. The shown alleles occur with an almost show that the respective pre-mRNA of the T-haplotype
100% linkage disequilibrium. Further details in [8]. differs significantly from that associated with the C hap-
lotype [8].
tein activation is the bottleneck for intracellular signal PREVALENCE OF THE C825T POLYMORPHISM
transduction. Therefore, it is sensible to assume that BY RACE
mutations or genetic polymorphisms that affect G pro- Initial studies for Caucasian populations showed that
tein function or expression have a strong impact on intra- approximately 10% carry the TT genotype, 45% the TC
cellular signal transduction, thereby also strongly de- genotype, and 45% the CC genotype [9]. This distribu-
termining drug responses. Rather than looking at SNPs tion is approximately the same throughout Europe, with
in different receptors, it appears attractive to investigate minor increases of the 825T allele frequencies in South-
SNPs in G protein subunits, which mediate the action ern Europe (e.g., Italy and Spain). However, “old” eth-
nicities show a quite different 825T allele frequency [9].of several tens to hundreds of receptors. This hypothesis
Australian aborigines, black Africans, and Afro-Ameri-also appears attractive in view of the fact that many of
cans show extremely high 825T allele frequencies, and thethe hitherto available cardiovascular drugs activate or
CC genotype occurs at a frequency of only 10%. Chineseinhibit G protein-coupled receptors or modulate the
and Japanese East Asians show an intermediate 825Tamount of hormone whose action involves G proteins.
allele frequency that lies between the Caucasian andThe G protein family consists of at least 16 different
African distribution. Thus, in contrast to what was ini--subunits, five different -subunits, and 12 -subunits
tially believed, the 825T allele represents the wild typeencoded by different genes, splice variants not being
for humans. The strong accumulation of the 825T allelementioned here [5]. Hence, it was impossible to predict
in Africans may partially explain their increased risk forfrom the functional data on lymphoblasts summarized
hypertension and obesity, which is dependent on life-above the G protein subunit or gene, respectively, re-
style. Moreover, the differential responsiveness of white
sponsible for enhanced G protein activation. and black Americans toward many drugs (e.g., antihy-
pertensives) may partially be explained by these differ-
ences in 825T allele frequencies.DISCOVERY OF THE GNB3
C825T POLYMORPHISM
VASCULAR REACTIVITY IN 825TFollowing systematic sequencing of genes encoding
ALLELE CARRIERSfor G protein subunits expressed in lymphoblasts and
fibroblasts [6] from hypertensive subjects, we detected The enhanced signal transduction associated with the
a silent C825T polymorphism in exon 10 of the gene 825T allele led to the hypothesis that in these individuals
cardiovascular reactivity could be enhanced.GNB3 that encodes the 3 subunit of G protein [2]. The
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Baumgart et al [10] were the first to study coronary Systemic infusion of the -adrenoceptor blocker propa-
nolol into healthy young normotensive men evoked anvasoconstriction on bolus injection of an 2-adrenocep-
increased fall in stroke volume in 825T allele carriers [13].tor agonist. In fact, 825T allele carriers showed an almost
A recent study suggests a stronger effect of the centrallytwofold enhanced coronary vasoconstriction compared to
acting 2-adrenoceptor agonist clonidine in healthy youngindividuals with the CC genotype. Interestingly, no such
men carrying at least one 825T allele [abstract; Mitchell Adifferences were observed on injection of an 1-adreno-
et al, Naunyn-Schmiedeberg’s Arch Pharmacol 365:R113,ceptor agonist, suggesting that in the coronary micro-
2002]. In these individuals, the fall in both systolic andcirculation, 1–adrenoceptor-induced vasoconstriction is
diastolic blood pressure was significantly increased, andmediated by G- protein heterotrimers not comprising
the release of noradrenaline more suppressed comparedthe G3 subunit. These findings of an increased agonist-
to homozygous individuals with CC genotype.induced coronary vasoconstriction were confirmed by
Finally, one large study examined whether GNB3 ge-others using methylergonovine maleate [11]. Wenzel et
notype might determine the blood pressure responseal [12] examined genotype-dependent vasoconstriction
to hydrochlorothiazide in white and black hypertensiveof blood vessels in the skin microcirculation in response
Americans [14]. Both in blacks and in whites, bloodto noradrenaline, angiotensin II, and endothelin I in the
pressure decreases were more pronounced in 825T allele
skin microcirculation [12]. Heterozygous 825T allele car-
carriers with a clear allele-dose effect. Other univariate
riers responded with significantly increased vasoconstric- predictors of enhanced blood pressure responses in-
tion to all three agonists. Interestingly, the increased cluded black race, female sex, higher pretreatment blood
vasoconstriction to noradrenaline in 825T allele carriers pressure, older age, lower waist-to-hip ratio, and mea-
became stronger in the presence of the 2-adrenoceptor sures of lower renin-angiotensin-aldosterone system
blocker yohimbine and the NO-synthase inhibitor L-nitro- activity. After the effects of the other predictors were
monomethyl-arginine (L-NMMA). This suggests that va- considered, the TT genotype remained a significant pre-
sodilator substances released from the endothelium can dictor of greater declines in systolic and diastolic blood
counteract increased vasoconstriction in healthy 825T pressures.
allele carriers with intact endothelium.
Scha¨fers et al [13] examined azepexol-induced vaso-
CONCLUSIONSconstriction in the dorsal hand vein and found no evi-
Although we are just on the way to understanding howdence for an increased vasoconstriction in 825T allele
pharmacogenetics may, in the future, help in decisioncarriers. Likewise, systemic infusion of the 2-adreno-
making regarding cardiovascular drug therapy, the GNB3ceptor agonist -methylnoradrenaline caused no exag-
C825T polymorphism appears an attractive candidategerated blood pressure response in 825T allele carriers
gene to be tested in large clinical trials for its appropriate-[13]. This may be explained by the fact that increased
ness of a relevant pharmacogenetics marker. Data accu-2–adrenoceptor-mediated release of vasodilator sub-
mulated thus far hold the promise that GNB3 is, in fact,stances from the endothelium is enhanced.
a good candidate due to its broad applicability, unlike
SNPs in receptors.
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